SevenBridge Financial Group LLC Buys 727 Shares of Johnson & Johnson (NYSE:JNJ)

SevenBridge Financial Group LLC boosted its stake in Johnson & Johnson (NYSE:JNJ) by 1.6% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 46,218 shares of the company’s stock after acquiring an additional 727 shares during the quarter. Johnson & Johnson accounts for 1.3% of SevenBridge Financial Group LLC’s portfolio, making the stock its 15th largest position. SevenBridge Financial Group LLC’s holdings in Johnson & Johnson were worth $7,166,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. bought a new stake in shares of Johnson & Johnson in the first quarter worth $765,000. Lavaca Capital LLC boosted its stake in shares of Johnson & Johnson by 1.3% during the 1st quarter. Lavaca Capital LLC now owns 6,418 shares of the company’s stock worth $1,015,000 after buying an additional 85 shares during the last quarter. Kinloch Capital LLC grew its holdings in shares of Johnson & Johnson by 13.8% in the 1st quarter. Kinloch Capital LLC now owns 16,009 shares of the company’s stock valued at $2,532,000 after acquiring an additional 1,944 shares in the last quarter. Waverly Advisors LLC increased its position in shares of Johnson & Johnson by 30.1% in the first quarter. Waverly Advisors LLC now owns 100,631 shares of the company’s stock valued at $15,919,000 after acquiring an additional 23,297 shares during the last quarter. Finally, Bayesian Capital Management LP bought a new stake in Johnson & Johnson during the first quarter worth about $3,275,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have weighed in on JNJ shares. Royal Bank of Canada boosted their price target on Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 16th. Citigroup upped their price target on shares of Johnson & Johnson from $180.00 to $185.00 and gave the stock a “buy” rating in a research report on Wednesday, October 16th. Guggenheim lifted their price objective on shares of Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a research report on Wednesday, November 6th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 14th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a report on Wednesday, October 16th. Seven equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $175.94.

Johnson & Johnson Stock Down 0.2 %

JNJ opened at $155.17 on Friday. The stock has a fifty day moving average of $160.21 and a 200-day moving average of $156.26. The company has a market capitalization of $373.59 billion, a P/E ratio of 22.46, a P/E/G ratio of 2.76 and a beta of 0.53. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $168.85. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The firm had revenue of $22.47 billion during the quarter, compared to the consensus estimate of $22.17 billion. During the same quarter in the previous year, the firm posted $2.66 EPS. The business’s revenue for the quarter was up 5.2% compared to the same quarter last year. On average, equities analysts expect that Johnson & Johnson will post 9.93 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be issued a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $4.96 annualized dividend and a yield of 3.20%. Johnson & Johnson’s dividend payout ratio is presently 71.78%.

Insider Activity

In related news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the transaction, the vice president now owns 18,973 shares of the company’s stock, valued at $3,131,683.38. The trade was a 22.90 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.16% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.